| Document |
Document Title |
|
JP7221277B2 |
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:X-A-Y-L-R (I)which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function ...
|
|
JP7218364B2 |
The invention provides a compound of formula (I):or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, me...
|
|
JP7214086B2 |
The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXRα and/or LXKβ) and act preferably as inverse agonists of LXR.
|
|
JP2023502857A |
The present invention uses the formula (I) [wherein J, R3and R4is as defined herein] and pharmaceutically acceptable salts thereof. Said N-(heteroaryl)quinazolin-2-amine derivatives and pharmaceutically acceptable salts thereof are poten...
|
|
JP2023011775A |
To provide compounds for treatment of diseases (e.g., neurodegenerative diseases).The present invention provides compounds of Formula (I-I) and salts thereof [in the Formula, R1, R2 and R3 are each independently selected from the group c...
|
|
JP2023502415A |
The present invention relates to compounds of formula (I) and to methods of treatment using said compounds. The compounds of the invention may be used in combination with antibacterial agents to treat bacterial infections. More specifica...
|
|
JP7208420B2 |
The invention discloses a method for fluoroalkylation of enamines with a fluoro alkyl halide in the presence of a base.
|
|
JP7202315B2 |
The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity:wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the pr...
|
|
JP7195356B2 |
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
|
|
JP7190612B2 |
Provided are compounds represented by the following formulas (I), (II), (III) and (IV) having orexin type 2 receptor-activating activity, or their pharmaceutically acceptable salts.
|
|
JP7185681B2 |
Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I):including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R3, R4, R5, ...
|
|
JP2022551197A |
Compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein the substituents are as defined herein, are described. Pharmaceutical compositions containing such compounds and methods of using same are also described. [Ch...
|
|
JP2022550873A |
The present invention relates to compound derivatives containing 6-7 bicyclic rings and uses thereof. The compounds according to the invention act as protein arginine methyltransferase 5 (PRMT5) inhibitors and can therefore be effectivel...
|
|
JP7181287B2 |
Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in prevent...
|
|
JP2022549545A |
The present invention provides anticholinergic compounds such as Umeclidinium bromide, Tiotropium bromide, Glycopyrronium bromide, Acridinium bromide, Ipratropium bromide (V) in continuous flow mode in the presence of one or more polar a...
|
|
JP2022549227A |
The present invention provides substituted saturated and unsaturated N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and medical disorders such as cancer, lysosomal accumulation in...
|
|
JP2022548747A |
The present invention provides substituted N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and medical disorders in patients such as cancer, lysosomal storage diseases, neurodegene...
|
|
JP2022547088A |
A compound of formula (I) below, or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof. (I) where Ra, Rb, Rc, Rd, X1, X2, R1~R4, W, Z, and L are defined as in the Summary of the Invention section. Further disclo...
|
|
JP2022546863A |
The present invention is based on the formula(I): (During the ceremony,R1,R2,andR3is as described herein)or a pharmaceutically acceptable salt, enantiomer, or diastereomer thereof, and compositions containing and methods of using the com...
|
|
JP2022545314A |
Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-related disorders, such as frontotemporal dementia (FTD).
|
|
JP7158577B2 |
Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
|
|
JP7158500B2 |
Provided is a compound of Formula (I):wherein the variable groups are defined herein.
|
|
JP2022544463A |
The present invention relates to compounds for the treatment of diseases or disorders including depression, erectile dysfunction, anxiety, sexual dysfunction and/or ejaculation disorders; or combinations thereof. [Selection drawing] Fig. 26
|
|
JP7156199B2 |
A resist composition comprising a base polymer and a quencher in the form of an amine compound having an iodized aromatic ring bonded to the nitrogen atom via a divalent hydrocarbon group offers a high sensitivity and minimal LWR or impr...
|
|
JP2022544055A |
Provided herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and diseases, disorders, or disorders that would benefit from modula...
|
|
JP7152430B2 |
This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions...
|
|
JP2022543106A |
Provided herein are compounds that inhibit HDAC6, a protein whose activity is associated with various diseases (eg, cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and dis...
|
|
JP2022145976A |
To provide an agent that effectively alleviates the exacerbation of amnesia caused by Parkinson disease and involves few side effects, and a novel velusetrag derivative.An agent for alleviating the exacerbation of amnesia caused by Parki...
|
|
JP2022542183A |
The present invention provides a compound or pharmaceutically acceptable polymorphs, solvates, enantiomers, stereoisomers, prodrugs, hydrates and/or derivatives thereof, an effective amount of formula I, formula II, formula III , to phar...
|
|
JP7135026B2 |
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treati...
|
|
JP7105691B2 |
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.For Formula I compounds X, Y, ...
|
|
JP2022533436A |
Compounds that act as CYP46A1 inhibitors, compositions containing these compounds, and their use for treating neurodegenerative diseases and the like, or pharmaceutically active salts thereof, are described herein. The present invention ...
|
|
JP2022533023A |
Provided herein are compounds, compositions, and methods useful for the regulation of integrated stress response (ISR) and for the treatment of related diseases, disorders, and diseases.
|
|
JP2022532354A |
The present invention inhibits NOD-like receptor protein 3 (NLRP3) inflammasome activity, according to formula (I): (in formula, R).1, R2, R3, R4, R5And Z relate to the novel pyridazine-3-ylphenol compounds (as defined herein). The prese...
|
|
JP7098716B2 |
The invention provides compounds of formula (I):or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides cry...
|
|
JP7091596B2 |
Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
|
|
JP7083750B2 |
The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
|
|
JP2022527294A |
The present disclosure relates to therapeutic methods or agents in inflammatory diseases and specific neuropathy associated with inflammatory signaling processes including, but not limited to, compounds, pharmaceutical compositions conta...
|
|
JP7076741B2 |
The present invention relates to novel and excellent small-molecule-compounds that specifically antagonize BMP signal pathways, and these compounds can be used to modulate cell growth, differentiation, proliferation, and apoptosis, and t...
|
|
JP2022071046A |
To provide compounds for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners, and the uses thereof.The present application is directed to compoun...
|
|
JP7065180B2 |
The present invention provides in one aspect azabicyclo and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, t...
|
|
JP2022524759A |
The present invention relates to a carboxamide-pyrimidine derivative of General Formula I, or a pharmaceutically acceptable salt thereof, and the use of a compound of the present invention for the treatment of hyperproliferative diseases...
|
|
JP2022524820A |
The present invention relates to the field of pharmaceuticals, in particular, (a) an inert substrate and (b) 2-[(1R, 3r, 5S) -3-({5-cyclopropyl-3- [2- (trifluoro)). Methoxy) phenyl] -1,2-oxazol-4-yl} methoxy) -8-azabicyclo [3.2.1] octane...
|
|
JP2022065101A |
To provide compounds containing a sulfonic group as KAT inhibitors.The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.SELECTED DRAWING: None
|
|
JP2022064180A |
To provide a heterocyclic compound with orexin type 2 receptor agonist activity.A compound represented by formula (I), where each symbol is as described in the specification, or a salt thereof has orexin type 2 receptor agonist activity ...
|
|
JP2022523332A |
The present specification provides esters and amide compounds and compositions of 8-methyl-8-azabicyclo [3.2.1] octane-3-yl and pyridine-4-ylmethanyl. Also provided herein are methods of preventing or delaying the onset of myopia in a su...
|
|
JP2022523154A |
Small molecule splicing regulator compounds that regulate the splicing of mRNAs such as pre-mRNA encoded by genes, pharmaceutical compositions containing them, and small molecule splicing regulators for regulating splicing and treating d...
|
|
JP2022523148A |
The use of small molecule splicing regulator compounds that regulate the splicing of mRNAs, such as gene-encoded pre-mRNA, and small molecule splicing regulator compounds for regulating splicing and treating diseases and conditions is de...
|
|
JP7051829B2 |
The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and d...
|
|
JP2022521467A |
Small molecule splicing regulator compounds that regulate the splicing of mRNAs such as pre-mRNA encoded by genes, pharmaceutical compositions containing them, and small molecule splicing regulators for regulating splicing and treating d...
|
